home / stock / msclf / msclf quote
Last: | $0.32 |
---|---|
Change Percent: | 7.06% |
Open: | $0.2974 |
Close: | $0.32 |
High: | $0.32 |
Low: | $0.2974 |
Volume: | 2,000 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.32 | $0.2974 | $0.32 | $0.32 | $0.2974 | 2,000 | 05-06-2024 |
$0.32 | $0.31025 | $0.32 | $0.325 | $0.31025 | 103,130 | 05-02-2024 |
$0.3193 | $0.3193 | $0.3193 | $0.3193 | $0.3193 | 1,000 | 05-01-2024 |
$0.332 | $0.33 | $0.332 | $0.35 | $0.33 | 18,750 | 04-30-2024 |
$0.3301 | $0.3495 | $0.3301 | $0.3495 | $0.3301 | 20,239 | 04-29-2024 |
$0.3301 | $0.33 | $0.3301 | $0.3437 | $0.33 | 15,017 | 04-25-2024 |
$0.3407 | $0.34075 | $0.3407 | $0.34075 | $0.3407 | 1,200 | 04-23-2024 |
$0.3598 | $0.3598 | $0.3598 | $0.3598 | $0.3598 | 15,080 | 04-22-2024 |
$0.371 | $0.39395 | $0.371 | $0.39395 | $0.371 | 29,150 | 04-19-2024 |
$0.3901 | $0.3901 | $0.3901 | $0.3901 | $0.3901 | 1,000 | 04-18-2024 |
$0.3895 | $0.3587 | $0.3895 | $0.3895 | $0.3587 | 90,000 | 04-17-2024 |
$0.37 | $0.36185 | $0.37 | $0.37 | $0.36185 | 18,855 | 04-16-2024 |
$0.3717 | $0 | $0.3717 | $0 | $0 | 20 | 04-15-2024 |
$0.3717 | $0.3717 | $0.3717 | $0.3717 | $0.3717 | 15,000 | 04-12-2024 |
$0.34 | $0.3456 | $0.34 | $0.3456 | $0.3306 | 46,451 | 04-11-2024 |
$0.36 | $0.4576 | $0.36 | $0.4576 | $0.36 | 29,987 | 04-10-2024 |
$0.39 | $0.4576 | $0.39 | $0.4576 | $0.3656 | 30,263 | 04-08-2024 |
$0.41 | $0.41 | $0.41 | $0.41 | $0.41 | 4,005 | 04-04-2024 |
$0.4162 | $0.4032 | $0.4162 | $0.4162 | $0.4032 | 2,000 | 04-03-2024 |
$0.4448 | $0 | $0.4448 | $0 | $0 | 1,000 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
OTCMKTS Market:
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at...
- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues to be on track to initiate first-in-human clinical trials mid-2024 - Cash balance of $39.6 million as at December 31, 2023 ...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder an...